Download - Cc cjdf gr 2012 8-13
![Page 1: Cc cjdf gr 2012 8-13](https://reader034.vdocuments.site/reader034/viewer/2022051515/55934f561a28ab283c8b474f/html5/thumbnails/1.jpg)
Creutzfeldt-Jakob DiseaseCreutzfeldt-Jakob DiseaseDiagnosis & ManagementDiagnosis & Management
Creutzfeldt-Jakob DiseaseCreutzfeldt-Jakob DiseaseDiagnosis & ManagementDiagnosis & Management
August 13, 2012August 13, 2012
Florence Kranitz, President, CJD FoundationFlorence Kranitz, President, CJD Foundation
Brian Appleby, M.D., Staff, Lou Ruvo Center for Brain HealthBrian Appleby, M.D., Staff, Lou Ruvo Center for Brain Health
Pierluigi Gambetti, M.D., Director, NPDPSC, Case WesternPierluigi Gambetti, M.D., Director, NPDPSC, Case Western
![Page 2: Cc cjdf gr 2012 8-13](https://reader034.vdocuments.site/reader034/viewer/2022051515/55934f561a28ab283c8b474f/html5/thumbnails/2.jpg)
NO RELEVANT FINANCIAL NO RELEVANT FINANCIAL DISCLOSURESDISCLOSURES
NO RELEVANT FINANCIAL NO RELEVANT FINANCIAL DISCLOSURESDISCLOSURES
![Page 3: Cc cjdf gr 2012 8-13](https://reader034.vdocuments.site/reader034/viewer/2022051515/55934f561a28ab283c8b474f/html5/thumbnails/3.jpg)
ObjectivesObjectivesObjectivesObjectives
I.I. Understand key elements of diagnosing Understand key elements of diagnosing CJDCJD
II.II. Demonstrate strategies for managing Demonstrate strategies for managing patients with CJDpatients with CJD
III.III. Demonstrate knowledge regarding the Demonstrate knowledge regarding the resources of the CJD Foundation & resources of the CJD Foundation & NPDPSCNPDPSC
![Page 4: Cc cjdf gr 2012 8-13](https://reader034.vdocuments.site/reader034/viewer/2022051515/55934f561a28ab283c8b474f/html5/thumbnails/4.jpg)
““Pri-on”Pri-on”““Pri-on”Pri-on”
• proproteinaceous teinaceous and and ininfectiousfectious
• --ionion (infectious, e.g. (infectious, e.g. virionvirion))
• No nucleic acidNo nucleic acid
• Non-degradable by typical Non-degradable by typical sterilizationsterilization
![Page 5: Cc cjdf gr 2012 8-13](https://reader034.vdocuments.site/reader034/viewer/2022051515/55934f561a28ab283c8b474f/html5/thumbnails/5.jpg)
Soto C, Trends Biochem Sci 2006
![Page 6: Cc cjdf gr 2012 8-13](https://reader034.vdocuments.site/reader034/viewer/2022051515/55934f561a28ab283c8b474f/html5/thumbnails/6.jpg)
![Page 7: Cc cjdf gr 2012 8-13](https://reader034.vdocuments.site/reader034/viewer/2022051515/55934f561a28ab283c8b474f/html5/thumbnails/7.jpg)
Age at OnsetAge at OnsetAge at OnsetAge at Onset
vCJDgCJD
sCJD
Adapted from: Appleby BS, J Neuropsychiatry Clin Neurosci 2007
![Page 8: Cc cjdf gr 2012 8-13](https://reader034.vdocuments.site/reader034/viewer/2022051515/55934f561a28ab283c8b474f/html5/thumbnails/8.jpg)
EpidemiologyEpidemiologyEpidemiologyEpidemiology
sCJD=1/1,000,000 people per year1/10,000 deaths per year
![Page 9: Cc cjdf gr 2012 8-13](https://reader034.vdocuments.site/reader034/viewer/2022051515/55934f561a28ab283c8b474f/html5/thumbnails/9.jpg)
Survival TimeSurvival TimeSurvival TimeSurvival Time
Adapted from: Appleby BS, Arch Neurol 2009
![Page 10: Cc cjdf gr 2012 8-13](https://reader034.vdocuments.site/reader034/viewer/2022051515/55934f561a28ab283c8b474f/html5/thumbnails/10.jpg)
Definitive DiagnosisDefinitive DiagnosisDefinitive DiagnosisDefinitive Diagnosis
H & E Immunohistochemistry
![Page 11: Cc cjdf gr 2012 8-13](https://reader034.vdocuments.site/reader034/viewer/2022051515/55934f561a28ab283c8b474f/html5/thumbnails/11.jpg)
Probable sCJDProbable sCJDProbable sCJDProbable sCJD
At least two clinical signs:1.Dementia2.Cerebellar or visual symptoms3.Pyramidal or extrapyramidal symptoms4.Akinetic mutism
At least one of the following:1.PSWC on EEG2.14-3-3 in CSF and disease duration < 2 years3.High signal abnormalities in basal ganglia or at least two cortical regions (temporal, parietal, or occipital) on DWI/FLAIR brain MRI
Zerr I, et al. Brain 2009
![Page 12: Cc cjdf gr 2012 8-13](https://reader034.vdocuments.site/reader034/viewer/2022051515/55934f561a28ab283c8b474f/html5/thumbnails/12.jpg)
Electroencephalogram (EEG)Electroencephalogram (EEG)Electroencephalogram (EEG)Electroencephalogram (EEG)
Periodic sharp wave complexes (PSWC’s)
![Page 13: Cc cjdf gr 2012 8-13](https://reader034.vdocuments.site/reader034/viewer/2022051515/55934f561a28ab283c8b474f/html5/thumbnails/13.jpg)
MRI (DWI/FLAIR)MRI (DWI/FLAIR)MRI (DWI/FLAIR)MRI (DWI/FLAIR)
![Page 14: Cc cjdf gr 2012 8-13](https://reader034.vdocuments.site/reader034/viewer/2022051515/55934f561a28ab283c8b474f/html5/thumbnails/14.jpg)
Acquired Prion DiseaseAcquired Prion DiseaseAcquired Prion DiseaseAcquired Prion Disease
![Page 15: Cc cjdf gr 2012 8-13](https://reader034.vdocuments.site/reader034/viewer/2022051515/55934f561a28ab283c8b474f/html5/thumbnails/15.jpg)
Iatrogenic CJDIatrogenic CJDIatrogenic CJDIatrogenic CJD
Adapted from: Brown P, Neurology 2006
![Page 16: Cc cjdf gr 2012 8-13](https://reader034.vdocuments.site/reader034/viewer/2022051515/55934f561a28ab283c8b474f/html5/thumbnails/16.jpg)
227 total cases
Variant CJDVariant CJDVariant CJDVariant CJD
http://www.cjd.ed.ac.uk/vcjdworld.htm
![Page 17: Cc cjdf gr 2012 8-13](https://reader034.vdocuments.site/reader034/viewer/2022051515/55934f561a28ab283c8b474f/html5/thumbnails/17.jpg)
vCJD CharacteristicsvCJD CharacteristicsvCJD CharacteristicsvCJD Characteristics
Will RG, Lancet 1996
![Page 18: Cc cjdf gr 2012 8-13](https://reader034.vdocuments.site/reader034/viewer/2022051515/55934f561a28ab283c8b474f/html5/thumbnails/18.jpg)
Pulvinar SignPulvinar SignPulvinar SignPulvinar Sign
Zeidler M, Lancet 2000
![Page 19: Cc cjdf gr 2012 8-13](https://reader034.vdocuments.site/reader034/viewer/2022051515/55934f561a28ab283c8b474f/html5/thumbnails/19.jpg)
Creutzfeldt-Jakob Disease in the UK, 18th Annual Report, 2009
MM
MV
BSE1980’s
![Page 20: Cc cjdf gr 2012 8-13](https://reader034.vdocuments.site/reader034/viewer/2022051515/55934f561a28ab283c8b474f/html5/thumbnails/20.jpg)
Care and ManagementCare and ManagementCare and ManagementCare and Management
Education
Communication Implementation
![Page 21: Cc cjdf gr 2012 8-13](https://reader034.vdocuments.site/reader034/viewer/2022051515/55934f561a28ab283c8b474f/html5/thumbnails/21.jpg)
Intervals of CareIntervals of CareIntervals of CareIntervals of Care
I.I. Pre-clinical/Presentation PhasePre-clinical/Presentation Phase
II.II. Diagnostic PhaseDiagnostic Phase
III.III. Caring PhaseCaring Phase
![Page 22: Cc cjdf gr 2012 8-13](https://reader034.vdocuments.site/reader034/viewer/2022051515/55934f561a28ab283c8b474f/html5/thumbnails/22.jpg)
Preclinical/Presentation PhasePreclinical/Presentation PhasePreclinical/Presentation PhasePreclinical/Presentation Phase• Initial interactions with primary Initial interactions with primary
medical doctormedical doctor
• At risk individuals should identify At risk individuals should identify “physician champions”“physician champions”
Kranitz FJ & Simpson DM. CNS Neurol Disord Drug Targets 2009
![Page 23: Cc cjdf gr 2012 8-13](https://reader034.vdocuments.site/reader034/viewer/2022051515/55934f561a28ab283c8b474f/html5/thumbnails/23.jpg)
Diagnosis PhaseDiagnosis PhaseDiagnosis PhaseDiagnosis Phase
• Discuss process with patient and familyDiscuss process with patient and family
• Don’t forget about present needsDon’t forget about present needs
• Refer to organizations and clinicians Refer to organizations and clinicians familiar with the illnessfamiliar with the illness
• Discharge planning (Discharge planning (beforebefore discharge) discharge)
• Must establish a “key worker”Must establish a “key worker”
Douglas M, Patients with nvCJD and their families 1999
![Page 24: Cc cjdf gr 2012 8-13](https://reader034.vdocuments.site/reader034/viewer/2022051515/55934f561a28ab283c8b474f/html5/thumbnails/24.jpg)
Caring PhaseCaring PhaseCaring PhaseCaring Phase
• Frequent reassessment/symptomatic Frequent reassessment/symptomatic treatmenttreatment
• Limit visits to few individuals of short Limit visits to few individuals of short durationsdurations
• Assess caregiver requirementsAssess caregiver requirements
• Hospice/Respite careHospice/Respite care
![Page 25: Cc cjdf gr 2012 8-13](https://reader034.vdocuments.site/reader034/viewer/2022051515/55934f561a28ab283c8b474f/html5/thumbnails/25.jpg)
Symptomatic TreatmentSymptomatic TreatmentSymptomatic TreatmentSymptomatic TreatmentSymptom Suggested Treatment
Psychosis/Agitation Low potency neuroleptics (e.g., quetiapine)
Myoclonus/Hyperstartle Long acting benzodiazepines (e.g., diazepam)Anticonvulsants (e.g., valproic acid)
Seizures Anticonvulsants
Dystonia/Contractures Passive movement Long acting benzodiazepines, Botulinum toxin injections
Constipation Bowel regimen (e.g., dulcolax)
Dysphagia/Rumination Thickener, cueing
Behavioral/Environmental changes first
Start low and go slow
Re-evaluate frequently
![Page 26: Cc cjdf gr 2012 8-13](https://reader034.vdocuments.site/reader034/viewer/2022051515/55934f561a28ab283c8b474f/html5/thumbnails/26.jpg)
AfterwardsAfterwardsAfterwardsAfterwards
• Arrange requested post-mortems prior to Arrange requested post-mortems prior to death death (www.cjdsurveillance.com)(www.cjdsurveillance.com)
• Frequent check-ins with family/caregiversFrequent check-ins with family/caregivers
• If postmortem performed, communicate If postmortem performed, communicate results (in person if possible)results (in person if possible)
• Encourage contact as neededEncourage contact as needed
![Page 27: Cc cjdf gr 2012 8-13](https://reader034.vdocuments.site/reader034/viewer/2022051515/55934f561a28ab283c8b474f/html5/thumbnails/27.jpg)
SummarySummarySummarySummary
• Diagnosing CJD can be difficult and Diagnosing CJD can be difficult and frustratingfrustrating
• Getting a proper diagnosis and managing Getting a proper diagnosis and managing the care of a patient with CJD is stressfulthe care of a patient with CJD is stressful
• Care and management of patients with Care and management of patients with prion disease is supportive and entails prion disease is supportive and entails several disease specific interventionsseveral disease specific interventions